EGFR and non-small cell lung carcinoma: In the current study, we monitored EGFR mutations during treatment with erlotinib in a group of patients with NSCLC, all of whom demonstrated sensitizing EGFR mutations in plasma DNA before the initiation of treatment with erlotinib.